非器质性心脏病心房颤动的治疗策略进展

doi:10.3969/j.issn.1004-583X.2016.01.008

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 30-33.doi: 10.3969/j.issn.1004-583X.2016.01.008

非器质性心脏病心房颤动的治疗策略进展

丁超

白求恩国际和平医院心内科,河北石家庄 050082

收稿日期:2015-11-03 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 丁超, Email: dingch2001@163.com
作者简介:丁超,白求恩国际和平医院心血管内科副主任,主任医师,医学博士,硕士研究生导师。中华医学会心血管分会预防学组全国委员,中国医师协会心律学会青年委员,河北省医学会心电生理与心脏起搏分会常委。研究方向:冠心病、心律失常心衰的介入治疗及基础研究。

Progress of treatment strategy in atrial fibrillation with non-structural heart disease

Ding Chao

Department of Cardiology, Bethune International Peace Hospital, Shijiazhuang 050082, China

Received:2015-11-03 Online:2016-01-05 Published:2016-04-19
Contact: Ding Chao, Email: dingch2001@163.com

摘要/Abstract

摘要： 心房颤动(房颤)是一种常见的心律失常。根据房颤的症状和时程可分为首发房颤、阵发性房颤、持续性房颤、长程持续性房颤和永久性房颤。根据血流动力性是否稳定和病程长短,可选择复律维持窦性心律策略、心室率控制策略和长期抗凝策略。新型口服抗凝剂可作为传统口服抗凝药物(OAC)的替代选择。除了药物治疗措施之外,房颤进行导管消融的地位逐渐提高,特别是对于非器质性心脏病的阵发性房颤患者,已经从过去的药物治疗失败后的可选治疗策略发展成为一线治疗策略。

关键词: 心房颤动, 抗凝血药

Abstract: Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Based on the symptom and duration, AF can be clinically classified into five types: first detected, paroxysmal, persistent, long-standing persistent and permanent AF. According to the haemodynamic condition and duration, rhythm-control strategy (conversion and maintenance of sinus rhythm), rate-control strategy and continuous anticoagulation strategy are optional. Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists (VKAs). The status of catheter ablation improves gradually, especially for the paroxysmal AF with non-structural heart disease, and now catheter ablation has been considered as a first line treatment and may be prior to anti-arrhythmic drug therapy in symptomatic paroxysmal AF with non-structural heart disease.

Key words: atrial fibrillation, anticoagulants

中图分类号:

R541.75

丁超. 非器质性心脏病心房颤动的治疗策略进展[J]. 临床荟萃, 2016, 31(1): 30-33.

Ding Chao. Progress of treatment strategy in atrial fibrillation with non-structural heart disease[J]. Clinical Focus, 2016, 31(1): 30-33.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.008

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/30

参考文献

[1] European Heart Rhythm Association.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2010,31(19):2369-2429.
[2] Patel NJ, Deshmukh A, Pant S.Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning[J]. Circulation,2014,129(23):2371-2379.
[3] 黄从新,马长生,杨延宗,等.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志, 2006,10(3):167-190.
[4] Singh S, Zoble RG, Yellen L.Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study[J]. Circulation,2000,102(19):2385-2390.
[5] Singh BN, Singh SN, Reda DJ.Amiodarone versus sotalol for atrial fibrillation[J]. N Engl J Med,2005,352(18):1861-1872.
[6] Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study[J]. Arch Intern Med,2005,165(10):1185-1191.
[7] 凌兰.338例急诊就诊心房颤动患者临床分析[D].北京:中国协和医科大学, 2009.
[8] Lip GY, Halperin JL, Tse HF. The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an evolution or revolution[J].Chest,2011,139(4):738-741.
[9] Olesen JB, Fauchier L, Lane DA, Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project[J]. Chest,2012,141(1):147-153.
[10] 徐荣,郭金成,郭明.老年心房颤动患者华法林长期抗凝治疗的效果与安全性[J]. 临床荟萃,2015,30(3):272-275.
[11] Banerjee A, Clementy N, Haguenoer K. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project[J].Am J Med,2014,127(10):972-978.
[12] Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial[J]. Lancet, 2006,367(9526):1903-1912.
[13] Connolly SJ, Ezekowitz MD, Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151.
[14] Patel MR, Mahaffey KW, Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10): 1557-1559.
[15] Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992.
[16] Calkins H, Kuck KH, Cappato R. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design[J]. Europace,2012,14(4):528-606.
[17] Deshmukh A, Patel NJ, Pant S. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures[J]. Circulation,2013,128(19):2104-2112.
[18] Park JW, Leithuser B, Gerk U. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes[J]. J Invasive Cardiol,2009,21(9):446-450.

非器质性心脏病心房颤动的治疗策略进展

Progress of treatment strategy in atrial fibrillation with non-structural heart disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	李雯琳, 张志. 心房颤动患者左心耳形态结构和功能与左心耳血栓及心源性卒中的关系研究进展[J]. 临床荟萃, 2024, 39(2): 168-171.
[3]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[4]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[5]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[6]	张海福, 叶向晴, 陈者旭, 陈施鉴, 杨栋, 张邢炜. 适量运动对心房颤动患者预后的影响:系统综述与Meta分析[J]. 临床荟萃, 2022, 37(6): 485-489.
[7]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[8]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[9]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[10]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10): 946-949.
[11]	赵美丽, 肖立远, 刘林, 康超, 张秋香. NT-proBNP、hs-CRP、LAD与慢性心力衰竭合并心房颤动的相关性[J]. 临床荟萃, 2021, 36(5): 412-415.
[12]	耿彦平，王立立，谷剑，齐鹏，陈淑霞. 抗凝治疗量表中文版效度及信度分析[J]. 临床荟萃, 2020, 35(9): 788-791.
[13]	马进才，马溶智，马珍珍. 利伐沙班对合并心功能不全的高龄非瓣膜性心房颤动疗效及安全性[J]. 临床荟萃, 2020, 35(5): 413-416.
[14]	杨华, 孟利民, 信栓力, 常超, 赵秀峰, 王民. 心房颤动患者血清趋化素水平与心房纤维化程度的相关性[J]. 临床荟萃, 2020, 35(3): 206-210.
[15]	陆玉琴, 李应东, 刘凯. 血清MMP-1、MMP-3、TIMP1及同型半胱氨酸水平在高血压并发心房颤动患者中的作用[J]. 临床荟萃, 2020, 35(11): 976-979.